SM
CNTX icon

Sabby Management’s Context Therapeutics CNTX Stock Holding History

Sabby Management’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,165,100
Closed -$2.53M – 132
2022
Q1 		$2.53M Sell
1,165,100
-65,730
-5% -$138K 0.38% 17
2021
Q4 		$3.27M Buy
+1,230,830
New +$6.14M 0.48% 30

Other funds holding CNTX

AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
V
Veritable Wilmington, Delaware $6.46B AUM 17.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
S
swisspartners Vaduz, Liechtenstein $78.4M AUM 9.82% 1-Year Est. Return

Sabby Management's CNTX Position: Q2 2022 in Review

Sabby Management sold out of Context Therapeutics (CNTX) in Q2 2022, closing a stake of 1,165,100 shares — an estimated $2.53M sold.

Sabby Management first reported a position in CNTX in Q4 2021 and held it in 2 quarters. The position peaked at $3.27M in Q4 2021. 20 funds tracked by Wall St. Rank hold CNTX as of Q2 2022.

  • Sabby Management reported no remaining Context Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Sabby Management sold 1,165,100 Context Therapeutics shares in Q2 2022, an estimated $2.53M.
  • Sabby Management first reported a position in Context Therapeutics in Q4 2021 and held it in 2 quarters.
  • Sabby Management's Context Therapeutics position peaked at $3.27M in Q4 2021.
  • 20 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2022.

Based on Sabby Management's 13F filing for Q2 2022, filed 15 Aug 2022.